팝업레이어 알림

팝업레이어 알림이 없습니다.


Innovation for

Global Leader
of Network

Clinical & non-clinical
pipeline with

  • Notice

      2021-10-19 합병종료 보고 공고
      2021-09-14 합병에 따른 채권자 이의제출 공고
      2021-08-27 소규모 합병 공고
      2021-08-18 [공지사항] 실질심사 결과 안내
      2021-08-12 반대의사표시 기준일 공고
  • Press Release

      2022-01-06 큐리언트, 美 FDA에 항암치료제 Q901 임상 1/2상 신청
      2021-12-14 큐리언트, 獨 자회사 QLi5 시리즈A1 "500만€ 유치"
      2021-11-23 큐리언트, MSD와 면역항암제 'Q702' 공동개발 계약 체결
      2021-11-23 Qurient Announces Collaboration Agreement with MSD to...
      2021-10-14 큐리언트 "면역항암제 Q702, 美 최대 암연구그룹서 소개"
  • Company

    Founded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model.See More

  • Business philosophy

    Innovation for unmet medical needs

    Qurient’s mission is to provide innovation for unmet medical needs to help patients around the world. Through fulfilling the mission, Qurient will be able to create concrete value for its shareholders. See More

  • Pipeline

    Qurient portfolio plan aims to achieve balanced innovation by strategic positioning of the R&D programs.See More

  • IR/PR

    Dear Qurient shareholders

    Qurient would like to share brief updates on current progress made on its portfolio programs. See More

information for download file